Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib versus placebo with omalizumab active control in adults with chronic spontaneous urticaria
2022-502161-19-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Novartis. Primary endpoints: Absolute change from baseline in UAS7 at Week 12, Absolute change from baseline in ISS7 at Week 12 and 1 more. Planned start Mar 2024; status: authorised.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2022-502161-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502161-19-00.